# Minimizing Hemorrhage Risk Strategies in Cervical Pregnancy—Stepwise Pharmacologic Priming and Delayed Surgical Evacuation: A Narrative Review

## TL;DR

This paper reviews strategies to manage rare cervical pregnancies while preserving fertility and reducing hemorrhage risks through stepwise drug use and delayed surgery.

## Contribution

A novel incremental dosing strategy combining mifepristone and methotrexate with Doppler-guided timing is proposed for cervical pregnancy management.

## Key findings

- Conservative strategies using methotrexate and mifepristone with Doppler monitoring reduce hemorrhage risks.
- A case demonstrated minimal blood loss using a stepwise pharmacologic protocol followed by delayed surgical evacuation.
- Adjuncts like hysteroscopy and embolization further improve outcomes in cervical pregnancy management.

## Abstract

Background: CP (CP) and HCP (HCP) are rare and high-risk conditions, often historically managed with radical intervention and associated with hemorrhage and fertility loss. Objective: To summarize current evidence on the conservative, fertility-preserving management of cervical and heterotopic cervical pregnancies and to illustrate a stepwise pharmacologic protocol applied in our tertiary center. Methods: A narrative literature review (PubMed, Scopus, Web of Science; inception—July 2025) was conducted using the following key terms: “CP,” “HCP,” “methotrexate,” “mifepristone,” “misoprostol,” “uterine artery embolization,” “hysteroscopy,” and “Doppler ultrasound.” We integrated a personal institutional case that applied stepwise pharmacologic priming, Doppler-guided surveillance, and delayed evacuation. Results: Evidence—primarily from case reports and small series—supports conservative, multi-modal strategies combining systemic or local methotrexate ± mifepristone, timed to Doppler-confirmed vascular regression, before surgical intervention. Adjuncts such as misoprostol, hysteroscopic resection, balloon tamponade, and uterine artery embolization further reduce hemorrhage risk while maintaining fertility. Our case utilized a novel, incremental dosing strategy of mifepristone followed by methotrexate, a week-long interval to confirm vascular involution via Doppler, and delayed suction curettage with minimal blood loss. Conclusions: Conservative, imaging-guided management is promising for reducing hemorrhagic complications and preserving fertility in CP/HCP. Future multicenter registries and standardized Doppler-based protocols are urgently needed to refine decision-making and optimize outcomes.